Bharat Immunologicals & Biologicals Corporation Limited (BIBCL)
BSE
8.73
-0.11 (-1.24%)
Closed
Oct 9, 2026
Day's Range
8.519.22
52 wk Range
7.1122.61
Financial Statements - BIBCL - Bharat Immunologicals & Biologicals Corporation Limited
Revenue
446.09M▼ 43.1%
Net Income
-166.38M▼ 90.1%Net Margin -37.3%
EBITDA
-154.92M▼ 280.4%
Free Cash Flow
108.92M▲ 125.9%
Income Statement
| Period Ending | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 |
|---|---|---|---|---|---|---|
| Sales | 446.09M | 783.88M | 853.33M | 668.36M | 836.45M | 347.98M |
| Cost of Goods | 422.08M | 660.46M | 883.49M | 619.21M | 796.87M | 299.06M |
| Gross Profit | 24M | 123.41M | -30.16M | 49.15M | 39.57M | 48.91M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -160.07M | -48.53M | -210.98M | -105.24M | -94.13M | -83.42M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | -222.67M | -96.87M | -242.07M | -142.03M | -73.73M | -79.58M |
| Income Tax | -56.29M | -9.33M | -60.95M | -39.91M | -15.80M | -36.97M |
| Net Income | -166.38M | -87.53M | -181.12M | -102.11M | -57.93M | -42.61M |
| EPS Basic | -3.85 | -2.03 | -4.194697 | -2.364822 | -1.341616 | -0.986985 |
| EPS Diluted | -3.85 | -2.03 | -4.194697 | -2.364822 | -1.341616 | -0.986985 |
| Basic Shares Outstanding | 43.18M | 43.18M | 43.18M | 43.18M | 43.18M | 43.18M |
| Diluted Shares Outstanding | 43.18M | 43.18M | 43.18M | 43.18M | 43.18M | 43.18M |
| Ebit | -153.05M | -45.78M | -198.44M | -101.40M | -59.16M | -71.33M |
| Ebitda | -154.92M | -40.72M | -202.02M | -99.03M | -56.40M | -71.20M |
| Net Income Continuous Operations | -222.67M | -96.87M | -242.07M | -142.03M | -73.73M | -79.58M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
